Causaly, a London, UK- and Athens, Greece-based provider of an AI platform for biomedical research, raised $60M in Series B funding.
The round, which brought the total amount to $93M, was led by ICONIQ Growth, with participation from Index Ventures, Marathon Venture Capital, EBRD, Pentech Ventures and Visionaries Club. Strategic individuals also participated in the round, including Alex Gorsky (former Chairman and CEO of Johnson & Johnson) and Olivier Pomel (CEO and Co-Founder of Datadog). In conjunction with the funding, Caroline Xie, general partner at ICONIQ Growth,, joined Causaly’s board of directors.
The company intends to use the funds to extend its product lead and expand commercial relationships.
Founded in 2018 and led by CEO Yiannis Kiachopoulos and CTO Artur Saudabayev, Causaly provides an AI platform for the modern Life Sciences research organizations, enabling them to find, analyze, and apply data in critical decision-making processes in drug discovery and development. Supporting a broad range of complex knowledge workflows, the platform accelerates the journey from bench research and laboratory insights to the launch of therapies.
Using a hybrid approach that combines a knowledge graph with advances in generative AI, Causaly enables researchers to conduct deep, unbiased scientific exploration. The technology is being adopted at scale by teams of researchers in diverse workflows from target identification to biomarker discovery, with customers including Gilead, Novo Nordisk, Regeneron, the Food and Drug Administration and the National Institute of Environmental Health Sciences.
FinSMEs
13/07/2023